The CHK1 inhibitor MU380 significantly increases the
sensitivity of human docetaxel-resistant prostate cancer cells
to gemcitabine through the induction of mitotic catastrophe

J 2020

The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe

DRÁPELA, Stanislav, PrashantKumar KHIRSARIYA, Wytske M VAN WEERDEN, Radek FEDR, Tereza SUCHÁNKOVÁ et. al.

Základní údaje

Originální název

The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe

Autoři

DRÁPELA, Stanislav (203 Česká republika, domácí), PrashantKumar KHIRSARIYA (356 Indie, domácí), Wytske M VAN WEERDEN (528 Nizozemské království), Radek FEDR (203 Česká republika), Tereza SUCHÁNKOVÁ (203 Česká republika), Diana BÍZOVA (203 Česká republika), Jan ČERVENÝ (203 Česká republika), Aleš HAMPL (203 Česká republika, domácí), Martin PUHR (40 Rakousko), William R WATSON (372 Irsko), Zoran CULIG (372 Irsko), Lumír KREJČÍ (203 Česká republika, domácí), Kamil PARUCH (203 Česká republika, domácí) a Karel SOUČEK (203 Česká republika, garant, domácí)

Vydání

Molecular oncology, Hoboken, Wiley, 2020, 1574-7891

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10608 Biochemistry and molecular biology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 6.603

Kód RIV

RIV/00216224:14310/20:00116570

Organizační jednotka

Přírodovědecká fakulta

DOI

http://dx.doi.org/10.1002/1878-0261.12756

UT WoS

000548858200001

Klíčová slova anglicky

castration-resistant prostate cancer; checkpoint kinase 1; docetaxel resistance; gemcitabine; mitotic catastrophe; MU380

Štítky

14110513, 14110517, podil, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 20. 2. 2023 08:13, Mgr. Marie Šípková, DiS.

Anotace

V originále

As treatment options for patients with incurable metastatic castration-resistant prostate cancer (mCRPC) are considerably limited, novel effective therapeutic options are needed. Checkpoint kinase 1 (CHK1) is a highly conserved protein kinase implicated in the DNA damage response (DDR) pathway that prevents the accumulation of DNA damage and controls regular genome duplication. CHK1 has been associated with prostate cancer (PCa) induction, progression, and lethality; hence, CHK1 inhibitors SCH900776 (also known as MK-8776) and the more effective SCH900776 analog MU380 may have clinical applications in the therapy of PCa. Synergistic induction of DNA damage with CHK1 inhibition represents a promising therapeutic approach that has been tested in many types of malignancies, but not in chemoresistant mCRPC. Here, we report that such therapeutic approach may be exploited using the synergistic action of the antimetabolite gemcitabine (GEM) and CHK1 inhibitors SCH900776 and MU380 in docetaxel-resistant (DR) mCRPC. Given the results, both CHK1 inhibitors significantly potentiated the sensitivity to GEM in a panel of chemo-naive and matched DR PCa cell lines under 2D conditions. MU380 exhibited a stronger synergistic effect with GEM than clinical candidate SCH900776. MU380 alone or in combination with GEM significantly reduced spheroid size and increased apoptosis in all patient-derived xenograft 3D cultures, with a higher impact in DR models. Combined treatment induced premature mitosis from G1 phase resulting in the mitotic catastrophe as a prestage of apoptosis. Finally, treatment by MU380 alone, or in combination with GEM, significantly inhibited tumor growth of both PC339-DOC and PC346C-DOC xenograft models in mice. Taken together, our data suggest that metabolically robust and selective CHK1 inhibitor MU380 can bypass docetaxel resistance and improve the effectiveness of GEM in DR mCRPC models. This approach might allow for dose reduction of GEM and thereby minimize undesired toxicity and may represent a therapeutic option for patients with incurable DR mCRPC.

Návaznosti

EF16_025/0007381, projekt VaV

Název: Preklinická progrese nových organických sloučenin s cílenou biologickou aktivitou

LM2015063, projekt VaV

Název: Národní infrastruktura chemické biologie (Akronym: CZ-OPENSCREEN)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CZ-OPENSCREEN: National Infrastructure for Chemical Biology

Citovat

DRÁPELA, Stanislav, PrashantKumar KHIRSARIYA, Wytske M VAN WEERDEN, Radek FEDR, Tereza SUCHÁNKOVÁ, Diana BÍZOVA, Jan ČERVENÝ, Aleš HAMPL, Martin PUHR, William R WATSON, Zoran CULIG, Lumír KREJČÍ, Kamil PARUCH a Karel SOUČEK. The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe. Molecular oncology. Hoboken: Wiley, 2020, roč. 14, č. 10, s. 2487-2503. ISSN 1574-7891. Dostupné z: https://dx.doi.org/10.1002/1878-0261.12756.

@article{1683057,
   author = {Drápela, Stanislav and Khirsariya, PrashantKumar and van Weerden, Wytske M and Fedr, Radek and Suchánková, Tereza and Bízova, Diana and Červený, Jan and Hampl, Aleš and Puhr, Martin and Watson, William R and Culig, Zoran and Krejčí, Lumír and Paruch, Kamil and Souček, Karel},
   article_location = {Hoboken},
   article_number = {10},
   doi = {http://dx.doi.org/10.1002/1878-0261.12756},
   keywords = {castration-resistant prostate cancer; checkpoint kinase 1; docetaxel resistance; gemcitabine; mitotic catastrophe; MU380},
   language = {eng},
   issn = {1574-7891},
   journal = {Molecular oncology},
   title = {The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe},
   url = {https://doi.org/10.1002/1878-0261.12756},
   volume = {14},
   year = {2020}
}

TY  - JOUR
ID  - 1683057
AU  - Drápela, Stanislav - Khirsariya, PrashantKumar - van Weerden, Wytske M - Fedr, Radek - Suchánková, Tereza - Bízova, Diana - Červený, Jan - Hampl, Aleš - Puhr, Martin - Watson, William R - Culig, Zoran - Krejčí, Lumír - Paruch, Kamil - Souček, Karel
PY  - 2020
TI  - The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe
JF  - Molecular oncology
VL  - 14
IS  - 10
SP  - 2487-2503
EP  - 2487-2503
PB  - Wiley
SN  - 15747891
KW  - castration-resistant prostate cancer
KW  - checkpoint kinase 1
KW  - docetaxel resistance
KW  - gemcitabine
KW  - mitotic catastrophe
KW  - MU380
UR  - https://doi.org/10.1002/1878-0261.12756
L2  - https://doi.org/10.1002/1878-0261.12756
N2  - As treatment options for patients with incurable metastatic castration-resistant prostate cancer (mCRPC) are considerably limited, novel effective therapeutic options are needed. Checkpoint kinase 1 (CHK1) is a highly conserved protein kinase implicated in the DNA damage response (DDR) pathway that prevents the accumulation of DNA damage and controls regular genome duplication. CHK1 has been associated with prostate cancer (PCa) induction, progression, and lethality; hence, CHK1 inhibitors SCH900776 (also known as MK-8776) and the more effective SCH900776 analog MU380 may have clinical applications in the therapy of PCa. Synergistic induction of DNA damage with CHK1 inhibition represents a promising therapeutic approach that has been tested in many types of malignancies, but not in chemoresistant mCRPC. Here, we report that such therapeutic approach may be exploited using the synergistic action of the antimetabolite gemcitabine (GEM) and CHK1 inhibitors SCH900776 and MU380 in docetaxel-resistant (DR) mCRPC. Given the results, both CHK1 inhibitors significantly potentiated the sensitivity to GEM in a panel of chemo-naive and matched DR PCa cell lines under 2D conditions. MU380 exhibited a stronger synergistic effect with GEM than clinical candidate SCH900776. MU380 alone or in combination with GEM significantly reduced spheroid size and increased apoptosis in all patient-derived xenograft 3D cultures, with a higher impact in DR models. Combined treatment induced premature mitosis from G1 phase resulting in the mitotic catastrophe as a prestage of apoptosis. Finally, treatment by MU380 alone, or in combination with GEM, significantly inhibited tumor growth of both PC339-DOC and PC346C-DOC xenograft models in mice. Taken together, our data suggest that metabolically robust and selective CHK1 inhibitor MU380 can bypass docetaxel resistance and improve the effectiveness of GEM in DR mCRPC models. This approach might allow for dose reduction of GEM and thereby minimize undesired toxicity and may represent a therapeutic option for patients with incurable DR mCRPC.
ER  -

DRÁPELA, Stanislav, PrashantKumar KHIRSARIYA, Wytske M VAN WEERDEN, Radek FEDR, Tereza SUCHÁNKOVÁ, Diana BÍZOVA, Jan ČERVENÝ, Aleš HAMPL, Martin PUHR, William R WATSON, Zoran CULIG, Lumír KREJČÍ, Kamil PARUCH a Karel SOUČEK. The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe. \textit{Molecular oncology}. Hoboken: Wiley, 2020, roč.~14, č.~10, s.~2487-2503. ISSN~1574-7891. Dostupné z: https://dx.doi.org/10.1002/1878-0261.12756.

Podrobný výpis o publikaci